Journal article
A definition and classification of status epilepticus - Report of the ILAE Task Force on Classification of Status Epilepticus
E Trinka, H Cock, D Hesdorffer, AO Rossetti, IE Scheffer, S Shinnar, S Shorvon, DH Lowenstein
Epilepsia | Published : 2015
DOI: 10.1111/epi.13121
Abstract
The Commission on Classification and Terminology and the Commission on Epidemiology of the International League Against Epilepsy (ILAE) have charged a Task Force to revise concepts, definition, and classification of status epilepticus (SE). The proposed new definition of SE is as follows: Status epilepticus is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t1). It is a condition, which can have long-term consequences (after time point t2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type ..
View full abstractGrants
Funding Acknowledgements
Dr. Trinka has received research funding from UCB Pharma, Biogen-Idec, Red Bull, Merck, the European Union, FWF Osterreichischer Fond zur Wissenschaftsforderung, and Bundesministerium fur Wissenschaft und Forschung and has acted as a paid consultant to Eisai, Takeda, Ever Neuropharma, Biogen Idec, Medtronics, Bial, and UCB and has received speakers' honoraria from Bial, Eisai, GL Lannacher, GlaxoSmithKline, Boehringer, Viropharma, Actavis, and UCB Pharma. He has no specific conflicts relevant to this work. Dr. Cock has served as a paid consultant for Special Products Ltd and Eisai Europe Ltd, and received support from UCB pharma, GlaxoSmithKline, and Lupin pharmaceuticals. Details at www.whopaysthisdoctor.org. She has no specific conflicts relevant to this work. Dr. Hesdorffer serves on Advisory Boards for Upsher-Smith and Acorda; is a consultant to Cyberonics, The Department of Rehabilitation Medicine at Mount Sinai Medical Center, and the Comprehensive Epilepsy Center at NYU Langone Medical Center; and is an Associate Editor of Epilepsia. She has no specific conflicts relevant to this work. Dr. Rossetti received research support from UCB Pharma and Sage Pharmaceuticals. He has no specific conflicts relevant to this work. Dr. Scheffer has no specific conflicts relevant to this work. Dr. Shinnar has served as consultant to Accorda, AstraZeneca, Questcor, and Upsher-Smith. He serves on a Daqta Safety Monitoring Board for UCB pharma. He has no specific conflicts relevant to this work. Dr. Shorvon has received research grants, or speakers or consultancy fees from Eisai, Viropharma, Sage, and Takeda. He has no specific conflicts relevant to this work. Dr. Lowenstein has served in the past as a paid consultant for Upsher-Smith, and his current work with the Human Epilepsy Project, a research project administered through the Epilepsy Study Consortium, is supported by UCB Pharma, Pfizer, Lundbeck, and Eisai, as well as various foundations. He has no specific conflicts relevant to this work. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guideline.